NR3C1 and asthma: Irusen et al[114] similarly suggested that the p38 MAPK pathway could be linked to changes in GR activity through in vivo and in vitro studies in asthma, respectively, confirming that p38 MAPK inhibitors can restore GC sensitivity in GC-resistant asthmatics.